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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the efficacy and safety of certolizumab pegol (CDP870) and if it has clinical benefits for people with rheumatoid arthritis
(RA) who do not respond well to conventional disease-modifying anti-rheumatic drugs (DMARDs).
B A C K G R O U N D
Rheumatoid arthritis (RA) is a systemic illness whose cause is un-
known, and which causes chronic inflammation of the joints. The
inflammatory response can lead to progressive joint destruction,
deformity and disability. Occasionally the illness can bring about
complications that affect organs and systems in the body other
than joints.
RA afflicts people of all ages and races equally and currently affects
0.5 to 1%of the population (Spector 1990). Populationprevalence
of 0.5% to 1% and a highly variable annual incidence (12-1200
per 100,000 population) depending on gender, race/ethnicity, and
calendar year (Gabriel 2001).
RA commonly starts between the ages of 40 and 60 and is three
times more common in women than men. Urban populations
seem tobemore often affected than rural populations for unknown
reasons (Gabriel 2003).
The prognosis of RA is very variable: those with persistent disease
may become severely disabled and life expectancy is reduced be-
tween 3 and 18 years especially in severe disease. Women have a
higher mortality rate than men (Gabriel 2003).
RA has a substantial socio-economic impact. In the USA the av-
erage annual medical cost per case is $5,919 (Yelin 1999) and ap-
proximately £2,600 (McIntosh 1996) in the UK. In Spain, RA
causes around 10% of total disability and 5% of transitory dis-
ability (Carmona 2002) and is commonly associated with occu-
1Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Protocol)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
pational disability (Doeglas 1995; Kaarela 1987).
Treatment objectives are to control symptoms of joint pain and
stiffness, improve function and quality of life and minimise the
risk of structural damage by reducing inflammation. These ob-
jectives may be met, and prognosis improved, by early treatment
with disease-modifying antirheumatic drugs (DMARDs), such as
methotrexate, (Laird 1990; Nell 2004). Tumour necrosis factor
alpha (TNF-alpha) a pro-inflammatory cytokine is a key player
in the pathogenesis of RA (Scott 2006). Inhibitors of TNF-al-
pha, of which three are currently licensed for use in Europe and
North America (adalimumab, etanercept, and infliximab), have
been a major development in the treatment of RA. Randomised
trials have shown that these drugs are highly effective in patients
with RA who have not responded well to conventional DMARDs.
TNF-alpha inhibitors have been shown to reduce the risk of joint
damage (van der Heijde 2004), improve physical function (Bruce
2003) and quality of life ( Chen 2006;Ware 2000). No controlled
trials have compared one TNF inhibitor against another (Scott
2006). An important limitation of their wider use is their high
cost, between $10,000 and $25,000 per patient per year.
Initial studies inRAwith a newpegylated anti-TNF, certolizumab,
(Fab fragment, pegylated anti-TNF alpha) suggest that it is well
tolerated and that clinical improvement is comparable to that ob-
tained with etanercept. The potential advantages of this drug are
its long life in plasma and low manufacturing costs (Choy 2002).
Pegylation of a molecule results in a longer half-life and thereby re-
duces the need for frequent dosing. However, lasting immunosup-
pression may be disadvantageous in the event of latent infections
such as tuberculosis or newly acquired infections or malignancies.
A systematic review of infliximab and adalimumab showed that
the risk of malignancy and serious infection was increased [pooled
odds ratios 3.3 (95% confidence interval [95% CI] 1.2 to 9.1)
and 2.0 (95% CI 1.3 to 3.1) respectively] (Bongartz 2006).
O B J E C T I V E S
To determine the efficacy and safety of certolizumab pegol
(CDP870) and if it has clinical benefits for people with rheuma-
toid arthritis (RA) who do not respond well to conventional dis-
ease-modifying anti-rheumatic drugs (DMARDs).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials.
Types of participants
Adults with RAwho have persistent disease activity despite current
or previous use of conventional disease modifying anti-rheumatic
drugs (DMARDs). Patients will be identified as fulfilling the usual
publishing ACR criteria for RA. Patients 18 years of age or older
meeting the ACR 1987 revised criteria (Arnett 1988) for RA. Pa-
tients must have had an active form of the disease as demonstrated
by at least two of the following symptoms:
1. 3 or more tender joint areas observed by a physician
2. 3 or more swollen joint areas observed by a physician
3. Duration of early morning stiffness > 30 minutes
4. Acute phase reactants such as Westergren erythrocyte sedimen-
tation rate (ESR) more than 100 mm/ hour or C reactive Protein
(CRP) more than 1 mg/mL
Types of interventions
The intervention is Certolizumab pegol (CDP870). The com-
parison drug may be a placebo or any disease-modifying anti-
rheumatic drug including other biologic agents used to treat RA.
Types of outcome measures
Primary outcomes
The primary outcomes for this systematic review will be the per-
cent of patients achieving an ACR 50, frequency of adverse events
(serious adverse events defined according to internationally ac-
cepted criteria, malignancies, and all infections, especially tuber-
culosis), and Health related quality of life such HAQ and SF-
36 when available. We will review also this list of adverse events:
headache, fever, blood disorders, laboratory disorders, abdomi-
nal pain, nasopharyngitis, nausea, respiratory tract infections, uri-
nary tract infections, neck pain, congestive heart failure, pruritus
and anaphylaxis. All causes of discontinuations will be analysed.
ACR50 is defined as a 50% improvement in the number of tender
and swollen joints and a 50% improvement in at least three of
the following items: observer evaluation of overall disease activ-
ity, patient evaluation of overall disease activity, patient evaluation
of pain, a score of physical disability, or improvements in blood
acute-phase responses.
Secondary outcomes
Secondary outcomes will be: ACR20 and ACR70 (a 20% or 70%
improvement in the parameters described above); Disease Activity
Score (DAS28 or other versions of DAS) and radiological changes.
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Search methods for identification of studies
This task will be conducted by the information specialist Anne
Fry-Smith. She will carry out the searches.
See search strategies in appendices section: MEDLINE Appendix
1; EMBASE Appendix 2; CINAHL Appendix 3; CDSR and
CENTRAL, HTA, DARE, NHS EED Appendix 4; SCOPUS
Appendix 5; TOXLINE (TOXNET) Appendix 6.
Electronic searches
The search strategy will be developed using a revision of the
Cochrane Highly Sensitive Search Strategy (HSSS) for PubMed
Glanville 2006 and the best sensitivity filter developed by the
Hedges Team Wong (a) 2006; Wong (b) 2006. The strategy in-
cludes MESH headings and text terms for CDP870 and Rheuma-
toid Arthritis. Safety data will be obtained from clinical trials. Sa-
fety data from published cohort studies will be summarized af-
ter implementing searches for cohort studies with Rheumatoid
arthritis. The search strategy will combine index and text terms
for CDP870 and adverse effects reported in RCT of Certoluz-
imab Pegol and another anti-TNF alpha with a strategy based
on Golder (a) 2006 strategy. No language restrictions will apply.
Search strategies to identify studies will follow theMusculoskeletal
Review Group recommendations.
A full range of databases will be reviewed including: TheCochrane
Controlled Trials Register (CENTRAL), MEDLINE, EMBASE,
Web of Knowledge, and Scopus. The Food and Drug Adminis-
tration (FDA) and the European Medicines Evaluation Agency
(EMEA) websites will also be searched. Lead researchers of identi-
fied studieswill be consulted in order to obtain additional informa-
tion, and also to ensure the completeness of the data sought. The
time-scale for the databases consulted:CENTRAL (TheCochrane
Library 2007, Issue 3); MEDLINE 1966 to October 2007; EM-
BASE (1980 to October 2007); HEED to October 2007. Scopus
2004 to October 2007.
Searching other resources
1. - Abstracts for the two key annual international rheumatol-
ogy meetings - the American College of Rheumatology and the
Congress of the European League Against Rheumatism - (2006-
December 2008) will be searched.
2. - We will consult the information made available by the
main researchers/sponsors and from the clinical trial meta-register
database (http://www.controlled-trials.com/mrct/). When pub-
lished data are missing, incomplete or inconsistent with RCT pro-
tocols, further information will be sought from the authors/man-
ufacturers.
3. - We will review the Health Technology Assessment reports
from the European, Canadian, North American and Australian
national agencies.
4. - We will inspect reference lists of all identified studies for more
trials.
5. - We will contact the manufacturers of Certolizumab for addi-
tional data.
Data collection and analysis
Selection of studies
Inclusion Criteria:
1. RCTs that compared Certolizumab pegol with any other agent
including placebo in adult RA patients with active rheumatoid
arthritis despite current or prior treatment with conventional dis-
ease modifying anti-rheumatic drugs (DMARDs).
2. Trials that are fully published as a paper or available as a complete
trial report will be included. Trial reports will be requested on all
major trials from the manufacturers especially where full data are
unpublished.
3.We will include all studies having at least 3 months of follow-up
in order to assess effectiveness. To assess safety we will also include
studies having a sub-optimal length of follow-up, from 8 weeks.
Exclusion criteria:
1. Trials of Certolizumab pegol in juvenile arthritis, Crohn’s dis-
ease, psoriatic arthritis and other forms of spondyloarthritis.
2. Trials ofCertolizumabpegol comparingdifferent doses or routes
without another active or placebo control group, (except for use
for assessing safety outcomes).
3. Studies reporting solely on laboratory measures aimed at in-
vestigating disease or treatment mechanisms and which did not
report relevant clinical outcomes.
4. Observational studies of Certolizumab pegol; interim results of
trials.
Safety outcomes
Will be obtained from all RCTs that meet the inclusion criteria
for the review on efficacy.
Data extraction and management
Two review authors will independently review titles and abstracts
of identified studies in the search to assess studies that may poten-
tially meet the inclusion criteria. We will resolve any disagreement
by discussion, and where doubt still remains, the full article will be
acquired for further inspection. Once the papers are obtained, we
will decide independently if the studies meet the review criteria.
Data included in previously published peer reviews will be ex-
tracted, when possible, for intention-to-treat populations as raw
numbers, plus any summary measures with standard deviations,
confidence intervals and P values of outcomes reported. Any dif-
ferences of opinion and data discrepancies will be resolved by in-
volvement of a third person (Encarnación Saiz).
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Through aWeb interface, VicenteRuiz&P Jobanputrawill decide
on which studies to include in the systematic review and will apply
exclusion criteria. Here a final table will be produced in Excel
format and data discrepancies will be resolved. Agreed data will be
used in meta-analyses and data synthesis.
Assessment of risk of bias in included studies
Following the recommendations of Cochrane Handbook, we will
use a risk of bias table to assess bias; in said table each entry ad-
dresses a specific feature of the study, the judgement for each entry
involves answering a question, with answers ’Yes’ indicating low
risk of bias, ’No’ indicating high risk of bias, and ’Unclear’ indi-
cating either lack of information or uncertainty over the potential
for bias. The resulting data will be presented in a risk of bias graph
(Higgins 2008).
Measures of treatment effect
Where possible, efforts will be made to convert outcome measures
to dichotomous data. For dichotomous data, risk ratios will be
calculated and their respective CIs ( Sinclair 1994). For continu-
ous data we will use mean differences when the results were mea-
sured in the same way in different studies. We will use standardised
mean differences when the results obtained were conceptually the
same but with different measurement scales. The central estimate
(mean) and standard deviation will be recorded. If this is not di-
rectly stated it will be calculated from the standard error, the dif-
ferent means and their respective CIs or P values. When medians
and interquartile ranges were the only data provided, the median
will be used as a proxy measure of the mean and the difference
between the first and third interquartile as equivalent to 1.35 of
the SD. It has been shown that RR is more intuitive (Boissel 1999)
than odds ratios and that odds ratios tend to be interpreted as RR
by clinicians (Higgins 2008). The risk difference will be used to
quantify the number needed to treat (NNT) (Laupacis 1988).
Unit of analysis issues
In most of the cases the design for a clinical trial will be a sim-
ple parallel group one, in which participants are individually ran-
domised to one of two intervention groups, and a single measure-
ment for each outcome from each participant is collected and anal-
ysed. However, there are numerous variations on this design which
we will take into account; for instance: 1) groups of individuals
being randomised together to the same intervention (i.e. cluster-
randomised trials); 2) individuals undergoing more than one in-
tervention (e.g. in a cross-over trial, or simultaneous treatment of
multiple sites on each individual), or 3) multiple observations for
the same outcome (e.g. repeated measurements, recurring events,
measurements on different body parts).
Dealing with missing data
We will carry out an intention-to-treat analysis. Everyone allo-
cated to the intervention will count whether they completed the
follow-up or not. We will assume that those who dropped out had
no change in their outcome. This rule is conservative concerning
response to treatment, because it assumes that those discontinu-
ing the studies would not have responded. It is not conservative
concerning adverse effects, but we felt that assuming that all those
leaving early would have developed side effects would overestimate
risk.
When published data is missing, incomplete or inconsistent with
RCT protocols or meeting abstracts, we will ask for further in-
formation from the authors/manufacturers. We will only exclude
abstracts of studies that are interim reports of studies that have not
yet finished recruiting.
Assessment of heterogeneity
Heterogeneity will be explored using funnel graphics (Light 1984)
and other graphics and estimators (Begg 1994; Egger 1997). We
will explore heterogeneity between the trials using the chi square
test for heterogeneity using a 10 % level of significance, and the
I squared (I2) test using a value of 50 % to represent moderate
levels of heterogeneity.
Assessment of reporting biases
Will be explored using funnel plots and heterogeneity.
Data synthesis
The need to analyse the results according to a fixed or random ef-
fect analysis will be explored (Laird 1990) or in the event of signif-
icant heterogeneity a decision may be made to not present a com-
bined result of the two (Schulz 1993). We will apply fixed-effect
models throughout, except when heterogeneity exists, in which
cases a random effects model will be used to introduce less bias
than excluding trials altogether. We will pool sufficiently homo-
geneous studies (e.g., similarities between participants, interven-
tions, outcome assessment, etc.). Forest plots (mean differences
and risk ratios) will be produced and written and graphic infor-
mation to justify the selection of certain models instead of others.
Data will be analysed with Review Manager 5.
We will use “The Grades of Recommendation, Assessment, De-
velopment and Evaluation” developed by the GRADE Working
Group for grading the quality of evidence. The GRADE approach
specifies four levels of quality. The highest quality rating is for
randomised trial evidence. Review authors can, however, down-
grade randomised trial evidence to moderate, low, or even very
low quality evidence, depending on the presence of five specific
factors [See Handbook chapter XII (Higgins 2008)].
A program called GRADEpro will assist in the creation of Sum-
mary of Findings Tables [see Handbook chapter XII (Higgins
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2008)]. Usually, quality rating will fall by one level for each factor,
up to a maximum of three levels. If there are very severe problems
for any one factor (e.g. when assessing limitations in design and
implementation, all studies were unconcealed, unblinded, and lost
over 50%of their patients to follow-up), randomised trial evidence
may fall by two levels due to that factor alone.
Subgroup analysis and investigation of heterogeneity
If heterogeneity were detected then a sub-group analysis would
be carried out (Yusuf 1991), and/or a meta-regression in order
to explain it (Thompson 1999). Subgroup analyses are planned
for the duration of the illness (approximately 3 years evolution,
patients’ sex, dose, administration and methodological quality).
Sensitivity analysis
We will perform sensitivity analyses by assessing different treat-
ment combinations, timing of drug initiation, trial design (ade-
quate allocation concealment, blinding of patients and outcome
assessors, andwithdrawals and dropouts less than 15%.Trial results
will be entered into RevMan 5 using the same plot direction to
enable the pooling of results where the lowest value has improved
and the highest value has worsened. Negative values in SMD will
indicate a benefit of the active drug over the placebo.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Search strategy for effectiveness:
1. (CDP870 or CDP 870 or “certolizumab pegol” or certolizumab or CDP-870 or cimzia).mp.
2. . (“Rheumatoid Arthritis” or (Caplan$ and Syndrome?) or (Felty$ and S?ndrome) or (Rheumatoid and Nodule?) or (Sjogren$ and
S?ndrome?) or (Sicca$ and S?ndrome?) or (Ankylos$ and Spondylit$) or (Spondylarthritis and Ankylopoietica) or (Rheumatoid$ and
Spondylit$) or (Bechterew$ and Disease?) or (Marie-Struempell and Disease?) or (Adult and Onset and Still$ and Disease?)).mp.
3.. exp Arthritis, Rheumatoid/
4. ( 2 OR 3)
5. 1 AND 4
6. Clinical trial.pt.
7. randomized.ab.
8. Placebo.ab.
9. dt.fs.
10. randomly.ab.
11. trial.ab.
12. groups.ab.
13. or/ 6-12
14. 5 and 13
Search strategy for Safety:
#1. Exp Headache/ci OR Exp Nasopharyngitis/ci OR Exp Arthritis, Rheumatoid/ci OR Exp Nausea/ci OR Exp Infection/ci OR Exp
Respiratory Tract Infections/ci OR Exp Urinary Tract Infections/ci OR Exp Neck Pain/ci OR Exp Antibodies, Antinuclear/ci OR Exp
Granulomatous Disease, Chronic/ci OR Exp Granulomatous Disease, Chronic/ci OR Exp Tuberculosis/ci OR Exp Histoplasmosis/
ci OR Exp Neoplasms/ci OR Exp Skin Neoplasms/ci OR Exp Hematologic Neoplasms/ci OR Exp Death/ci OR Exp Sepsis/ci OR
Exp Abdominal Pain/ci OR Exp Heart Failure, Congestive/ci OR Exp Fever/ci OR Exp Pruritus/ci OR Exp Melanoma/ci OR Exp
Lymphoma/ci OR Exp Pneumonia/ci OR Exp Lupus/ci OR Exp Lupus Erythematosus, Systemic/ci OR Exp Anaphylaxis/ci OR
“blood disorders”.ab,ti. OR “laboratory test abnormalities”.ab,ti. OR Headache.ab,ti. OR Nasopharyngitis.ab,ti. OR “Rheumatoid
Arthritis”.ab,ti. OR Nausea.ab,ti. OR Infection.ab,ti. OR “Respiratory Tract Infections”.ab,ti. OR “Urinary Tract Infections” .ab,ti.
OR “Neck Pain”.ab,ti. OR “Antinuclear Antibodies”.ab,ti. OR “Chronic Granulomatous Disease” .ab,ti. OR Tuberculosis.ab,ti. OR
Histoplasmosis.ab,ti. OR Neoplasms.ab,ti. OR “Skin Neoplasms”.ab,ti. OR “Hematologic Neoplasms”.ab,ti. OR Death.ab,ti. OR
Sepsis.ab,ti. OR “Abdominal Pain” .ab,ti. OR “Heart Failure”.ab,ti. OR Fever.ab,ti. OR Pruritus.ab,ti. OR Melanoma.ab,ti. OR
Lymphoma.ab,ti. OR Pneumonia.ab,ti. OR Lupus.ab,ti. OR “Lupus Erythematosus”.ab,ti. OR Anaphylaxis.ab,ti.
#2. ae.fs OR po.fs OR to.fs OR de.fs OR co.fs
#3. (advers$.ab,ti. OR untoward$.ab,ti. OR avers$.ab,ti. OR detrimental$.ab,ti. OR damage$.ab,ti. OR harmful$.ab,ti. OR crip-
ple$.ab,ti. OR prejudicial$.ab,ti. OR disruptiv$.ab,ti. OR destructive$.ab,ti. OR deleter$.ab,ti. OR untoward$.ab,ti. OR unex-
pect$.ab,ti. OR side$.ab,ti. OR serious$.ab,ti. OR severe$.ab,ti. OR unlikely$.ab,ti. OR malignan$.ab,ti.) AND (consequenc$.ab,ti.
OR implication$.ab,ti. OR result$.ab,ti. OR outgrowth$.ab,ti. OR repercussion$.ab,ti. OR episod$ .ab,ti. OR happen$.ab,ti. OR
reaction$.ab,ti. OR effect$.ab,ti. OR experience$.ab,ti.) OR complication$.tw.
#4. Exp Drug Toxicity
#5. 1 OR 2 OR 3 OR 4
#6. CDP870 OR CDP870 or CDP 870 or “certolizumab pegol” or certolizumab or CDP-870 or cimzia.mp.
#8. 5 AND 6
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Appendix 2. EMBASE search strategy
Search strategy for effectiveness:
1. ’rheumatoid arthritis’/exp/
2. ’certolizumab pegol’/exp/
3. (CDP870 OR ’CDP 870’ OR CDP-870 OR ’certolizumab pegol’ OR certolizumab OR cimzia).mp.
4. 2 OR 3
5. 4 AND 1
6. random:.tw.
7. clinical trial:.mp.
8. exp health care quality
9. or/6-8
10. 5 AND 9
Search strategy for safety:
#1 exp Headache/si or exp Nasopharyngitis/si or exp Arthritis, Rheumatoid/si or exp Nausea/si or exp Infection/si or exp Respiratory
Tract Infections/si or exp Urinary Tract Infections/si or exp Neck Pain/si or exp Antibodies, Antinuclear/si or exp Granulomatous
Disease, Chronic/si or exp Granulomatous Disease, Chronic/si or exp Tuberculosis/si or exp Histoplasmosis/si or exp Neoplasms/si
or exp Skin Neoplasms/si or exp Hematologic Neoplasms/si or exp Death/si or exp Sepsis/si or exp Abdominal Pain/si or exp Heart
Failure, Congestive/si or exp Fever/si or exp Pruritus/si or exp Melanoma/si or exp Lymphoma/si or exp Pneumonia/si or exp Lupus/
si or exp Lupus Erythematosus, Systemic/si or exp Anaphylaxis/si or “blood disorders”.ab,ti. or “laboratory test abnormalities”.ab,ti.
or Headache.ab,ti. or Nasopharyngitis.ab,ti. or “Rheumatoid Arthritis”.ab,ti. or Nausea.ab,ti. or Infection.ab,ti. or “Respiratory Tract
Infections”.ab,ti. or “Urinary Tract Infections”.ab,ti. or “Neck Pain”.ab,ti. or “Antinuclear Antibodies”.ab,ti. or “Chronic Granulo-
matous Disease”.ab,ti. or Tuberculosis.ab,ti. or Histoplasmosis.ab,ti. or Neoplasms.ab,ti. or “Skin Neoplasms”.ab,ti. or “Hematologic
Neoplasms”.ab,ti. or Death.ab,ti. or Sepsis.ab,ti. or “Abdominal Pain”.ab,ti. or “Heart Failure”.ab,ti. or Fever.ab,ti. or Pruritus.ab,ti. or
Melanoma.ab,ti. or Lymphoma.ab,ti. or Pneumonia.ab,ti. or Lupus.ab,ti. or “Lupus Erythematosus”.ab,ti. or Anaphylaxis.ab,ti.
#2 (ae or to or co).fs.
#3 (((advers$ or untoward$ or avers$ or detrimental$ or damage$ or harmful$ or cripple$ or prejudicial$ or disruptiv$ or destructive$
or deleter$ or untoward$ or unexpect$ or side$ or serious$ or severe$ or unlikely$ or malignan$) and (consequenc$ or implication$
or result$ or outgrowth$ or repercussion$ or episod$ or happen$ or reaction$ or effect$ or experience$)) or complication$).tw.
#4 exp Adverse drug reaction/ or exp Side-effect/ or exp Drug Toxicity
#5 or/1-4
#6 CDP870.rn OR (CDP870 or CDP 870 or “certolizumab pegol” or certolizumab or CDP-870 or cimzia).mp.
#7 5 AND 6
Appendix 3. CINAHL search strategy
Search strategy for effectiveness:
1.’rheumatoid arthritis’/exp/
2.“rheumatoid arthritis”.mp.
3. (CDP870 OR ’CDP 870’ OR CDP-870 OR ’certolizumab pegol’ OR certolizumab OR cimzia).mp.
4.(1 or 2) and 3
5.exp prognosis
6.exp study design
7.random:.mp.
8.or/ 5-7
9.4 and 8
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Appendix 4. Search strategy for CDSR and CENTRAL, HTA, DARE, NHS EED
Search strategy for effectiveness:
Cochrane Database of Systematic Reviews, Health Technology Assessment (HTA), The Database of Abstracts of Reviews of Effects
(DARE), NHS Economic Evaluation Database (NHS EED) from Ovid:
1.’rheumatoid arthritis’.mp.
2.(CDP870 OR ’CDP 870’ OR CDP-870 OR ’certolizumab pegol’ OR certolizumab OR cimzia).mp.
3.1 and 2
Search strategy for safety:
DARE, CDSR and CENTRAL from OVID platform (version 10.5.1), will be searched up to October 2007, The search strategy will
combine text and index terms for CDP870 and adverse effects reported in RCTs of Certoluzimab Pegol and another anti-TNF alpha
with a strategy based on that by Golder (b) 2006.
#1 Drug and ( hypersensitive$ or tocit$).tw.
#2 ((safe$ or advers$ or tolerabilit$ or toxic$ or adr$ or tolera$ or harm$ or complicat$ or risk$) adj20 objective$).tw.
#3 (side adj3 effect$ adj20 objective$).tw.
#4 (undesirable adj3 effect$ adj20 objetive$).tw.
#5 (treatment adj3 emergent adj20 objective$).tw.
#6 or/1-5
#7 (CDP870 or CDP 870 or certolizumab pegol or certolizumab or CDP-870 or cimzia).tw.
#8 6 and 7
Appendix 5. SCOPUS search strategy
Search strategy for effectiveness:
SCOPUS will be searched up to August of 2007, without limits of years:
KEY((certolizumab OR cimzia OR CDP-870 OR CDP870 OR “CDP 870”) AND (“rheumatoid arthritis” ))
Web of Knowledge (WOK), was searched up to August of 2007, without limits of years. The search strategy is as follows:
topic=((certolizumab OR cimzia OR CDP-870 OR CDP870 OR “CDP 870”) AND (“rheumatoid arthritis” )
Databases=MEDLINE, Current Contents Connect, Web of Science, Derwent Innovations Index, ISI Proceedings; Timespan=All Years
Appendix 6. TOXLINE (TOXNET) search strategy
Search strategy for safety:
TOXLINE (TOXNET) will be searched up to October 2007. The search strategy will combine index and text terms for CDP870:
#1. certolizumab OR “certolizumab pegol” OR CDP870 OR CDP-870 OR “CDP 870” OR cimzia
WH A T ’ S N E W
Date Event Description
3 April 2008 Amended CMSG ID: C001-P
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